PHARMAKES: what changed
Two financial years side by side, explained: what moved most in the balance sheet and the result, why the result rose or fell, and where the money went.
PHARMAKES
Largest movements
- Cash -€224,012
down €224,012 (-93.7%), from €239,171 to €15,160
mainly Advances received (-€247,775) and Debts after one year (-€68,908)
- Intangible fixed assets -€47,146
down €47,146 (-25.0%), from €188,582 to €141,436
- Deferred charges and accrued income -€24,448
down €24,448 (-95.9%), from €25,497 to €1,049
- Advances received -€247,775
down €247,775 (-100.0%), from €247,775 to €0
- Debts after one year -€68,908
down €68,908 (-12.7%), from €541,968 to €473,060
- Reserves +€32,749
up €32,749 (+2.9%), from €1.1m to €1.2m
of which Distributable reserves: +€32,749
- Gross operating margin -€124,691
down €124,691 (-56.6%), from €220,256 to €95,565
- Taxes -€36,359
down €36,359 (-58.8%), from €61,847 to €25,488
- Financial income +€8,984
up €8,984 (+33.4%), from €26,910 to €35,894
From the 2024 result to the 2025 result
Each bar is the change in one income-statement line, as its effect on the result: higher costs pull it down, higher income lifts it.
Cash bridge derived
Derived from the 2024 and 2025 balance sheets and the 2025 result: not a filed cash-flow statement. It shows where the money came from and went.
Every line side by side
| Line | Code | 2024 | 2025 | Change | % |
|---|---|---|---|---|---|
| Total assets | 20/58 | €2,038,761 | €1,743,323 | -€295,438 | -14.5% |
| Fixed assets | 21/28 | €834,698 | €775,159 | -€59,539 | -7.1% |
| Intangible fixed assets | 21 | €188,582 | €141,436 | -€47,146 | -25.0% |
| Tangible fixed assets | 22/27 | €56,288 | €43,895 | -€12,393 | -22.0% |
| Furniture and vehicles | 24 | €56,288 | €43,895 | -€12,393 | -22.0% |
| Financial fixed assets | 28 | €589,828 | €589,828 | = | 0.0% |
| Current assets | 29/58 | €1,204,063 | €968,164 | -€235,899 | -19.6% |
| Amounts receivable after more than one year | 29 | €0 | - | = | |
| Trade receivables | 290 | €0 | - | = | |
| Amounts receivable within one year | 40/41 | €939,395 | €951,955 | +€12,560 | +1.3% |
| Trade receivables | 40 | €201,153 | €1,184 | -€199,969 | -99.4% |
| Other amounts receivable | 41 | €738,242 | €950,771 | +€212,529 | +28.8% |
| Cash at bank and in hand | 54/58 | €239,171 | €15,160 | -€224,012 | -93.7% |
| Deferred charges and accrued income | 490/1 | €25,497 | €1,049 | -€24,448 | -95.9% |
| Total equity and liabilities | 10/49 | €2,038,761 | €1,743,323 | -€295,438 | -14.5% |
| Equity | 10/15 | €1,156,670 | €1,189,419 | +€32,749 | +2.8% |
| Contributions | 10/11 | €18,600 | €18,600 | = | 0.0% |
| Reserves | 13 | €1,138,070 | €1,170,819 | +€32,749 | +2.9% |
| Non-distributable reserves | 130/1 | €0 | - | = | |
| Reserves not available under the articles | 1311 | €0 | - | = | |
| Distributable reserves | 133 | €1,138,070 | €1,170,819 | +€32,749 | +2.9% |
| Profit (loss) carried forward | 14 | €0 | €0 | = | |
| Amounts payable | 17/49 | €882,091 | €553,904 | -€328,187 | -37.2% |
| Amounts payable after more than one year | 17 | €541,968 | €473,060 | -€68,908 | -12.7% |
| Financial debts | 170/4 | €541,968 | €473,060 | -€68,908 | -12.7% |
| Amounts payable within one year | 42/48 | €338,362 | €79,578 | -€258,785 | -76.5% |
| Current portion of amounts payable after more than one year | 42 | €70,636 | €71,430 | +€794 | +1.1% |
| Trade debts | 44 | €552 | €1,341 | +€790 | +143.2% |
| Suppliers | 440/4 | €552 | €1,341 | +€790 | +143.2% |
| Advances received on contracts in progress | 46 | €247,775 | €0 | -€247,775 | -100.0% |
| Taxes, remuneration and social security | 45 | €18,566 | €6,806 | -€11,760 | -63.3% |
| Taxes | 450/3 | €14,291 | €3,193 | -€11,098 | -77.7% |
| Remuneration and social security | 454/9 | €4,275 | €3,613 | -€662 | -15.5% |
| Other amounts payable | 47/48 | €834 | €1 | -€833 | -99.9% |
| Accrued charges and deferred income | 492/3 | €1,761 | €1,266 | -€494 | -28.1% |
| Non-recurring operating income | 76A | €0 | - | = | |
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets | 630 | €59,368 | €61,091 | +€1,723 | +2.9% |
| Other operating charges | 640/8 | €1,127 | €1,300 | +€174 | +15.4% |
| Non-recurring operating charges | 66A | €3,063 | €157 | -€2,906 | -94.9% |
| Gross operating margin | 9900 | €220,256 | €95,565 | -€124,691 | -56.6% |
| Operating profit (loss) | 9901 | €156,699 | €33,018 | -€123,682 | -78.9% |
| Financial income | 75/76B | €26,910 | €35,894 | +€8,984 | +33.4% |
| Recurring financial income | 75 | €26,910 | €35,894 | +€8,984 | +33.4% |
| Financial charges | 65/66B | €11,691 | €10,675 | -€1,016 | -8.7% |
| Recurring financial charges | 65 | €11,691 | €10,675 | -€1,016 | -8.7% |
| Profit (loss) for the period before taxes | 9903 | €171,918 | €58,237 | -€113,681 | -66.1% |
| Income taxes | 67/77 | €61,847 | €25,488 | -€36,359 | -58.8% |
| Profit (loss) for the period | 9904 | €110,072 | €32,749 | -€77,322 | -70.2% |
| Profit (loss) for the period to be appropriated | 9905 | €110,072 | €32,749 | -€77,322 | -70.2% |
Source: filed annual accounts (NBB), financial years ended 31 March 2024 and 31 March 2025. Colour: green is a favourable move for that line, red an unfavourable one. Prepared on 9 October 2026 via checked.be.